Overview

Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary

Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
It's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Docetaxel
Gemcitabine